inotersen
Commercial- Indications
- Hereditary transthyretin amyloidosis
Company intelligence / Profile preview
Akcea Therapeutics
Cambridge, Massachusetts, United Statesionis.com ↗
- Ownership
- Public · AKCA
- Employees
- ~200
- Development stage
- Commercial
01
Overview
Akcea has two commercially approved medicines: TEGSEDI (inotersen) for polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults, and WAYLIVRA (volanesorsen) for treatment of familial chylomicronemia syndrome. The company also has several drugs in clinical development, including AKCEA-TTR-LRx which showed up to 94% reduction in TTR in Phase 1 trials.
- Therapeutic areas
- NeurologyRare DiseasesCardiovascularMetabolic Disorders
- Modalities
- Antisense oligonucleotidesRNA-targeted therapeuticsLICA (Ligand Conjugated Antisense) technology
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →03
Partnerships
Beyond the preview
Go deeper on Akcea Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Akcea Therapeutics.